J&J declares Actelion tender offer a success, sees closing in second quarter

Features Reuters

  • FILE PHOTO:Bottles of Johnson's baby oil, made by Johnson & Johnson, are seen on a supermarket shelf in Seattle, Washington, U.S., February 10, 2017.  REUTERS/Chris Helgren

    FILE PHOTO:Bottles of Johnson's baby oil, made by Johnson & Johnson, are seen on a supermarket shelf in Seattle, Washington, U.S., February 10, 2017. REUTERS/Chris Helgren (Copyright Reuters 2017)

  • FILE PHOTO: A Johnson & Johnson building is shown in Irvine, California, U.S., January 24, 2017.   REUTERS/Mike Blake

    FILE PHOTO: A Johnson & Johnson building is shown in Irvine, California, U.S., January 24, 2017. REUTERS/Mike Blake (Copyright Reuters 2017)

  • FILE PHOTO: The company's logo is seen at the headquarters of Swiss biotech company Actelion in Allschwil, Switzerland January 26, 2017. REUTERS/Arnd Wiegmann

    FILE PHOTO: The company's logo is seen at the headquarters of Swiss biotech company Actelion in Allschwil, Switzerland January 26, 2017. REUTERS/Arnd Wiegmann (Copyright Reuters 2017)

Johnson & Johnson declared its $30 billion tender offer for Swiss biotechnology company Actelion successful on Friday, reporting it controlled 77.2 percent of the voting rights after the main offer period.

Continue Reading Below

The price of the offer, which J&J announced on Jan. 26, was $280 per share for Actelion. It said it expected the transaction to close in the second quarter.

J&J has said it intends to delist Actelion, while a new research and development company being spun out of Actelion, to be called Idorsia and led by Actelion founder Jean-Paul Clozel, will have a separate Swiss listing.

(Reporting by Michael Shields; editing by Brenna Hughes Neghaiwi)